Listar MD - Artículos por autor "Lichinitser, M."
Mostrando ítems 1-1 de 1
-
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot, X.; Verma, S.; Fallowfield, L.; Müller, M.; Lichinitser, M.; Jenkins, V.; Sánchez-Muñoz, Alfonso
; Machackova, Z.; Osborne, S.; Gligorov, J.[et al.] (Elsevier, 2017-09-28)
Aim: To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). Patients and methods: Post surgery and post chemotherapy in the (neo)adjuvant setting, ...